Journey Medical Résultats passés
Passé contrôle des critères 0/6
Journey Medical a connu une croissance annuelle moyenne de ses bénéfices de 21.6%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 10.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 0.3% par an.
Informations clés
21.63%
Taux de croissance des bénéfices
33.72%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.95% |
| Taux de croissance des recettes | 0.27% |
| Rendement des fonds propres | -31.10% |
| Marge nette | -14.82% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jun 24
DERM: Expanded Access And Parent Cash Backing Will Support Future Value
Analysts have raised their price target on Journey Medical by $1, citing updated valuations that reflect the implied value of its shares within Fortress Biotech. Supporting research keeps key assumptions unchanged, including fair value, discount rate, revenue growth, profit margin, and future P/E.Mise à jour du récit • Jun 03
DERM: Expanded Access Progress Will Support Future Parent Group Value
Narrative Update on Journey Medical The analyst price target for Journey Medical has been adjusted from $13.25 to $13.50, as analysts factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples influenced in part by recent Street research attention on both Journey Medical and its parent Fortress Biotech. Analyst Commentary Recent Street research around Journey Medical and Fortress Biotech has given investors more context on how analysts are thinking about value, execution, and growth for Journey Medical within the broader group structure.Mise à jour du récit • Apr 27
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.Mise à jour du récit • Apr 12
DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.
Nouveau récit • Apr 10
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Mar 28
DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
Nouveau récit • Mar 26
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Mar 11
DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).Mise à jour du récit • Feb 25
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).Mise à jour du récit • Feb 10
DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).Mise à jour du récit • Jan 27
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Article d’analyse • Jan 14
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Mise à jour du récit • Jan 12
DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.Mise à jour du récit • Dec 27
DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).Mise à jour du récit • Dec 12
DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.Mise à jour du récit • Nov 28
DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.Mise à jour du récit • Nov 14
DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.Article d’analyse • Aug 15
US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Mise à jour du récit • Aug 15
Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Article d’analyse • Aug 12
Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Apr 01
Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nouveau récit • Mar 30
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.Article d’analyse • Mar 25
A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Article d’analyse • Feb 06
Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jan 11
Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Article d’analyse • Oct 03
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Article d’analyse • Sep 14
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 06
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Mar 11
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Article d’analyse • Jan 18
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Journey Medical Corporation ( NASDAQ:DERM ) shares have retraced a considerable 33% in the last month, reversing a fair...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Journey Medical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 65 | -10 | 44 | 0 |
| 31 Dec 25 | 62 | -11 | 44 | 0 |
| 30 Sep 25 | 59 | -9 | 45 | 1 |
| 30 Jun 25 | 56 | -9 | 44 | 1 |
| 31 Mar 25 | 56 | -8 | 42 | 2 |
| 31 Dec 24 | 56 | -15 | 40 | 10 |
| 30 Sep 24 | 58 | -18 | 40 | 11 |
| 30 Jun 24 | 78 | 1 | 37 | 13 |
| 31 Mar 24 | 80 | -4 | 39 | 13 |
| 31 Dec 23 | 79 | -4 | 44 | 8 |
| 30 Sep 23 | 80 | -12 | 48 | 10 |
| 30 Jun 23 | 61 | -39 | 55 | 11 |
| 31 Mar 23 | 63 | -38 | 58 | 12 |
| 31 Dec 22 | 74 | -30 | 59 | 11 |
| 30 Sep 22 | 75 | -41 | 61 | 9 |
| 30 Jun 22 | 79 | -41 | 56 | 7 |
| 31 Mar 22 | 76 | -46 | 48 | 18 |
| 31 Dec 21 | 63 | -44 | 40 | 17 |
| 30 Sep 21 | 59 | -20 | 31 | 15 |
| 30 Jun 21 | 49 | -9 | 26 | 14 |
| 31 Mar 21 | 45 | 4 | 23 | 0 |
| 31 Dec 20 | 45 | 5 | 22 | 0 |
| 31 Dec 19 | 35 | 4 | 19 | 0 |
Des revenus de qualité: DERM n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: DERM n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: DERM n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 21.6% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de DERM au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: DERM n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( -6% ).
Rendement des fonds propres
ROE élevé: DERM a un retour sur capitaux propres négatif ( -31.1% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/26 23:07 |
| Cours de l'action en fin de journée | 2026/07/24 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Journey Medical Corporation est couverte par 5 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |